The South Korea ovarian cancer therapeutics market size stood at around USD xx billion in 2020 and is projected to reach xx billion by 2028, exhibiting a CAGR of around xx% during the forecast period.
Ovarian cancer is a disease in which, depending on the type and stage of the disease, malignant (cancerous) cells are found inside, near, or on the outer layer of the ovaries. The major symptoms of ovarian cancer include bloating, pelvic and abdominal pain, difficulty in eating, and urinary symptoms. Cancer is a leading cause of death in Korea. The incidences of ovarian cancer are high in women aged 55-64 years. According to GLOBOCAN report for year 2020, 2756 new cases of ovarian cancer were reported in South Korea. The number of deaths reported due to ovarian cancer were 1422.
Women above 60 years of age account for almost 57% of all ovarian cancer incidences and 75% of all ovarian cancer-related deaths, with a median age at diagnosis being 63 years. Thus, the increasing geriatric population is driving the growth of the ovarian cancer therapeutics market.
In 2015, 2,443 cases of ovarian cancer were reported in South Korea, while in 2020 the number rose to 2,756. Increase in incidence rate is another major factor propelling the market growth. Furthermore, initiatives taken by government is impacting the market positively. Delay in diagnosis might impede the growth of the market. Around 55.6% of ovarian cancers are detected in last stage in Korea.